Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib as primary treatment in newly diagnosed Ph+ chronic myeloid leukemia
KCT0000615Phase 4Not yet recruiting
- Sponsor
- Novartis
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Planned start Jan 2013; status: not yet recruiting.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on KCT0000615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000615.